Skip to main content

Table 4 The comparison and outcome analyses of the patients with monotherapy of tigecycline or sulbactam

From: Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex

Variables TG groupa SB groupa p Deceasedab Survivorsa p
n = 39 n = 13   n = 11 n = 41  
Demographic parameters
 Age, yr 71.4 (15.0) 68.7 (19.9) 0.899 75.3 (12.0) 69.5 (17.1) 0.439
 Male gender 25 (64.1) 10 (76.9) 0.506 8 (72.7) 27 (65.9) 1.000
Concomitant diseases
 Hepatic dysfunction 3 (7.7) 0 (0.0) 0.564 1 (9.1) 2 (4.9) 0.518
 Renal insufficiency 10 (25.6) 4 (30.8) 0.729 1 (9.1) 13 (31.7) 0.251
 Chronic pulmonary disease 11 (28.2) 4 (30.8) 1.000 4 (36.4) 11 (26.8) 0.709
 Heart disease 6 (15.4) 1 (7.7) 0.664 2 (18.2) 5 (12.2) 0.630
 Diabetes mellitus 9 (23.1) 4 (30.8) 0.714 3 (27.3) 10 (24.4) 1.000
 Immune compromise 8 (20.5) 1 (7.7) 0.420 2 (18.2) 7 (17.1) 1.000
 Malignancy 8 (20.5) 3 (23.1) 1.000 4 (36.4) 7 (17.1) 0.216
Surgery 9 (23.1) 1 (7.7) 0.419 2 (18.2) 8 (19.5) 1.000
Clinical conditions
 APACHE II Score 17.0 (6.1) 18.2 (6.0) 0.557 17.1 (6.8) 17.3 (5.9) 0.904
 Ventilator use 21 (53.8) 11 (84.6) 0.048 6 (54.5) 26 (63.4) 0.730
 Bilateral pneumonia 18 (46.2) 12 (92.3) 0.004 8 (72.7) 22 (53.7) 0.319
 Polymicrobial pneumonia 31 (79.5) 9 (69.2) 0.466 9 (81.8) 31 (75.6) 1.000
  With MRSA 20 (51.3) 6 (46.2) 0.749 5 (45.5) 21 (51.2) 0.734
  With Pseudomonas aeruginosa 14 (35.9) 3 (23.1) 0.506 5 (45.5) 12 (29.3) 0.470
  With Klebsiella spp. 7 (17.9) 1 (7.7) 0.662 1 (9.1) 7 (17.1) 1.000
  With Serratia marcescens 5 (12.8) 1 (7.7) 1.000 1 (9.1) 5 (12.2) 1.000
  With Stenotrophomanas maltophilia 3 (7.7) 3 (23.1) 0.157 1 (9.1) 5 (12.2) 1.000
 Multisite infections 14 (35.9) 5 (38.5) 1.000 4 (36.4) 15 (36.6) 1.000
  With urinary tract infection 7 (17.9) 3 (23.1) 0.697 2 (18.2) 8 (19.5) 1.000
  With catheter related infection 0 (0.0) 2 (15.4) 0.059 1 (9.1) 1 (2.4) 0.382
  With skin and soft tissue infection 3 (7.7) 1 (7.7) 1.000 1 (9.1) 3 (7.3) 1.000
  With intra-abdominal infection 4 (10.3) 0 (0.0) 0.561 0 (0.0) 4 (9.8) 0.567
  With invasive fungal infection 6 (15.4) 0 (0.0) 0.317 1 (9.1) 5 (12.2) 1.000
Microbiology
 MDR Acb complex with TG or SB resistancec 6 (15.4) 4 (30.8) 0.244 1 (9.1) 9 (22.0) 0.668
 Airway eradication of MDR Acb complexd 12 (34.3) 8 (88.9) 0.006 4 (57.1) 16 (43.2) 0.684
 Bacteremia during treatment 2 (5.1) 0 (0.0) 1.000 1 (9.1) 1 (2.4) 0.382
Treatment
 Tigecycline-based treatment     7 (63.6) 32 (78.0) 0.435
 Duration, days 13.8 (5.1) 12.7 (5.6) 0.293 11.9 (3.0) 14.0 (5.6) 0.398
 Delayed treatment 20 (51.3) 5 (38.5) 0.423 5 (45.5) 20 (48.8) 0.845
Outcomes
 Clinical resolution of pneumonia 26 (66.7) 8 (61.5) 0.747    
 Mortality during treatment 7 (17.9) 4 (30.8) 0.435    
 30-day mortality 10 (25.6) 7 (53.8) 0.089    
  1. Abbreviations: TG tigecycline, SB sulbactam, APACHE acute physiology and chronic health evaluation, MRSA methicillin resistant Staphylococcus aureus, MDR Acb multidrug resistant Acinetobacter calcoaceticus-Acinetobacter baumannii
  2. aCategorical data are no.(%) of subject, continuous data are expressed as mean (standard deviation)
  3. bMortality during treatment
  4. cThe initial airway MDR Acb complex isolates with resistance to TG in TG group, or with resistance to SB in SB group
  5. d35 patients in TG group and 9 in SB group; 7 patients in the deceased group and 37 in the survivors group had available data for evaluation